Last update 22 Jul 2025

Copper (64Cu) Oxodotreotide

Overview

Basic Info

Drug Type
Peptide Conjugate Radionuclide, Diagnostic radiopharmaceuticals
Synonyms
64-Cu-Dotatate, 64Cu-DOTA-tyr3-Octreotate, Copper Cu 64 dotatate
+ [4]
Target
Action
modulators
Mechanism
SSTR modulators(Somatostatin receptor modulators)
Therapeutic Areas
Active Indication
Originator Organization
Inactive Organization
License Organization
Drug Highest PhaseApproved
First Approval Date
United States (03 Sep 2020),
RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), Paediatric investigation plan (European Union)
Login to view timeline

Structure/Sequence

Molecular FormulaC65H87CuN14O19S2
InChIKeyIJRLLVFQGCCPPI-QMVMUTFZSA-K
CAS Registry1426155-87-4
Boost your research with our ADC technology data.
Boost your research with our ADC technology data.

External Link

KEGGWikiATCDrug Bank
D11882--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Neuroendocrine Tumors
United States
03 Sep 2020
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Somatostatin Receptor-Positive Neuroendocrine TumorPhase 3
United States
23 Aug 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
64Cu-DOTATATE PET/CT
mevfczqbtv(ooajwrlffi) = rqzrzlutpc ivscwlugax (arfcejdvwv )
-
01 Sep 2024
Not Applicable
-
Cu64-dotatate-PET/CT
addvpsnwyd(jkddovsptq) = zehllrkybu bykkwuehiy (nkbanvangu )
-
24 May 2024
Ga68-dotatate-PET/CT
addvpsnwyd(jkddovsptq) = ecybvxevvw bykkwuehiy (nkbanvangu )
Phase 3
63
yyjbdmlbci = bmhycqtivp atedebkaxs (dcumpvzqty, anqckspzib - jvutkavpbs)
-
22 Dec 2022
Phase 3
Somatostatinoma
Somatostatin Receptor-Positive
12
udcqxkaoqe(jdkeaisryg) = yorpmkxryl gqnqmprnzc (fiskgvziqr )
Positive
01 Jun 2020
Not Applicable
-
lhpezsscjs(fyhteqhdqi) = stvcgyhjnn ffpcdlnhlf (telydbtntp )
-
24 May 2016
lhpezsscjs(fyhteqhdqi) = magulyvllw ffpcdlnhlf (telydbtntp )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free